Amylyx Pharmaceuticals (AMLX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.38

Estimate

-$0.37

Surprise

-2.2%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Amylyx Pharmaceuticals (AMLX) reported a wider loss than forecast — adjusted EPS of -$0.38 against the -$0.37 estimate (a 2.2% shortfall).

• Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-05
• Amylyx Pharma Q3 EPS $(0.38), Inline — benzinga, 2026-11-05
• Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 — fiscal.ai, 2026-11-04

TrendMatrix currently rates AMLX Sell at 5.2/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -2.2% surprise compares with a -1.9% four-quarter average. Next scheduled report: 2027-03-04.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$29.50

Price target

$37.09

Stop

$27.44

Upside to target

+25.7%

Reward-to-risk

2.3:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$3.70B

P/E (fwd)

-27.1

52-week range

$10.83–$41.14

Off 52-week high

28.3%

RSI (14)

59

Volume vs avg

1.44×

Score today

5.2/10